IMPL
Impel NeuroPharma Inc. (IMPL)
$5.78
Market closed
Key Stats
$5.67
Day's Range
$6.2
$5.67
52-Week Range
$15.24
| Returns | |
| 1 month return | 26.65% |
| 3 month return | 42.89% |
| 1 year return | 56.38% |
| 5 year return | 39.22% |
Company Information
Impel NeuroPharma, Inc. is a late-stage pharmaceutical company focused on utilizing its proprietary technology to develop and commercialize transformative therapies for people suffering from diseases with high unmet needs, with an initial focus on diseases of the CNS. The Company’s strategy is to rapidly advance its product candidate pipeline that pairs its proprietary Precision Olfactory Delivery (POD®) system with well-established therapeutics, including TRUDHESA™ for the acute treatment of migraine, INP105 for the acute treatment of agitation and aggression in patients with autism, and INP107 for OFF episodes in Parkinson’s disease.
| Organization | Impel NeuroPharma Inc. |
| Employees | 59 |
| CEO | Mr. Adrian Adams |
Analyst Recommendation
based on 9 analysts ratings
Buy
88%
Buy
11%
Hold
0%
Sell
Based on 9 Wall street analysts offering stock ratings for Impel NeuroPharma Inc.(by analysts ranked 0 to 5 stars)
Recommendation Trend
Based on 9 analyst
| Current | 1M Ago | 3M Ago | |
| Buy | 8 | 8 | 8 |
| Hold | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 |
| Consensus | BUY | BUY | BUY |
Company Financials
Highlights
| Market Capitalization | 140.1M |
| Book Value | $0.17 |
| Dividend Share | 0.0 |
| Dividend Yield | 0.0% |
| Earnings Per Share (EPS) | -4.57 |
| Wall Street Target Price | 36.0 |
Valuation
| Trailing PE | 0.0 |
| Forward PE | 0.0 |
| Price/Book (mrq) | 40.13 |
| Enterprise Value | 109.4M |
| Enterprise Value/Revenue | 20.91 |
| Enterprise Value/Ebitda | -1.23 |
Technicals
| 50 Day MA | 7.74 |
| 200 Day MA | 7.72 |
Institutional Holdings
Kohlberg Kravis Roberts & Co LP
17.42%
Vivo Capital, LLC
12.15%
5AM Venture Management, LLC
12.15%
venBio Partners LLC
11.63%
Vanguard Group Inc
2.16%
DCF Advisers, LLC
1.85%
